Quince Therapeutics, Inc. Operating Lease Right-of-Use Assets
Quince Therapeutics, Inc. (QNCX) had Operating Lease Right-of-Use Assets of $0 as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-14
- 2026-06-30: Operating Lease, Right-of-Use Asset $0.00.
- 2026-03-31: Operating Lease, Right-of-Use Asset $415.00K.
- 2025-12-31: Operating Lease, Right-of-Use Asset $453.00K.
- 2025-09-30: Operating Lease, Right-of-Use Asset $481.00K.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $415.00K 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $453.00K 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $481.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $507.00K 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $493.00K 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $498.00K 10-K · filed 2026-04-10 | |
| 2024-09-30 | $559.00K 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $554.00K 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $498.00K 10-Q · filed 2025-05-13 | $576.00K 10-Q · filed 2024-05-13 |
| 2023-12-31 | $385.00K 10-K · filed 2025-03-24 | |
| 2023-09-30 | $48.00K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $110.00K 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $171.00K 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $291.00K 10-K · filed 2024-04-01 | |
| 2022-09-30 | $208.00K 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $328.00K 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $343.00K 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $1.17M 10-K · filed 2023-03-15 | |
| 2021-09-30 | $1.35M 10-Q · filed 2021-10-29 | |
| 2021-07-31 | $44.00M 10-K · filed 2023-03-15 | $44.00K 10-Q · filed 2021-10-29 |
| 2021-06-30 | $1.50M 10-Q · filed 2021-08-06 | |
| 2021-05-31 | $1.20M 10-K · filed 2023-03-15 | |
| 2021-03-31 | $500.00K 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $674.00K 10-K · filed 2022-03-01 | |
| 2020-09-30 | $848.00K 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $686.00K 10-Q · filed 2020-08-14 | |
| 2020-05-31 | $172.00K 10-K · filed 2023-03-15 | |
| 2020-03-31 | $637.00K 10-Q · filed 2020-05-12 | |
| 2019-12-31 | $625.00K 10-K · filed 2021-03-01 | |
| 2019-09-30 | $724.00K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $823.00K 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $815.00K 10-Q · filed 2019-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |